Published in J Clin Oncol on April 01, 2000
Population-based assessment of hospitalizations for toxicity from chemotherapy in older women with breast cancer. J Clin Oncol (2002) 2.09
Differences in management of older women influence breast cancer survival: results from a population-based database in Sweden. PLoS Med (2006) 1.79
Implementing a geriatric assessment in cooperative group clinical cancer trials: CALGB 360401. J Clin Oncol (2011) 1.76
Benefits and harms of mammography screening after age 74 years: model estimates of overdiagnosis. J Natl Cancer Inst (2015) 1.56
Breast cancer adjuvant chemotherapy decisions in older women: the role of patient preference and interactions with physicians. J Clin Oncol (2010) 1.27
Development and evaluation of a decision aid on mammography screening for women 75 years and older. JAMA Intern Med (2014) 1.18
Is adjuvant chemotherapy of benefit for postmenopausal women who receive endocrine treatment for highly endocrine-responsive, node-positive breast cancer? International Breast Cancer Study Group Trials VII and 12-93. Breast Cancer Res Treat (2008) 1.00
Letrozole in the neoadjuvant setting: the P024 trial. Breast Cancer Res Treat (2007) 0.98
Quality of Life in elderly patients with cancer. Health Qual Life Outcomes (2003) 0.95
Adjuvant therapy for women over age 65 with breast cancer. Dtsch Arztebl Int (2011) 0.92
Clinical feasibility of (neo)adjuvant taxane-based chemotherapy in older patients: analysis of >4,500 patients from four German randomized breast cancer trials. Breast Cancer Res (2008) 0.91
Age disparity in the dissemination of imatinib for treating chronic myeloid leukemia. Am J Med (2010) 0.90
Breast cancer in elderly women (≥ 80 years): variation in standard of care? J Surg Oncol (2010) 0.89
Cardiovascular complications of breast cancer therapy in older adults. Oncologist (2011) 0.85
Risk of subsequent dementia diagnoses does not vary by types of adjuvant chemotherapy in older women with breast cancer. Med Oncol (2008) 0.84
Attenuation of doxorubicin-induced cardiotoxicity by mdivi-1: a mitochondrial division/mitophagy inhibitor. PLoS One (2013) 0.84
Optimal management of the elderly patient with head and neck cancer: Issues regarding surgery, irradiation and chemotherapy. World J Clin Oncol (2015) 0.84
Second non-breast primary cancer following adjuvant therapy for early breast cancer: a report from the International Breast Cancer Study Group. Eur J Cancer (2008) 0.84
Preliminary Development and Evaluation of an Algorithm to Identify Breast Cancer Chemotherapy Toxicities Using Electronic Medical Records and Administrative Data. J Oncol Pract (2014) 0.83
Contribution of the Local RAS to Hematopoietic Function: A Novel Therapeutic Target. Front Endocrinol (Lausanne) (2013) 0.83
Compliance and toxicity of adjuvant CMF in elderly breast cancer patients: a single-center experience. BMC Cancer (2005) 0.82
Does chemotherapy-induced neutropaenia result in a postponement of adjuvant or neoadjuvant regimens in breast cancer patients? Results of a retrospective analysis. Br J Cancer (2007) 0.82
Treatment of older patients with HER2-positive metastatic breast cancer with pertuzumab, trastuzumab, and docetaxel: subgroup analyses from a randomized, double-blind, placebo-controlled phase III trial (CLEOPATRA). Breast Cancer Res Treat (2013) 0.81
Mammography Screening and Treatment of Breast Cancer in the Elderly. Breast Care (Basel) (2008) 0.78
Adjuvant Systemic Therapy in Older Breast Cancer Women: Can We Optimize the Level of Care? Cancers (Basel) (2015) 0.78
Effect of age on drug metabolism in women with breast cancer. Expert Opin Drug Metab Toxicol (2015) 0.78
[Comorbidity oriented oncology - an overview]. Wien Klin Wochenschr (2010) 0.78
Chemotherapy: Adjuvant chemotherapy in older patients with breast cancer. Nat Rev Clin Oncol (2009) 0.77
Quality of life assessment in women with breast cancer: a prospective study including hormonal therapy. J Breast Cancer (2013) 0.76
The Role of Supportive Therapy in the Era of Modern Adjuvant Treatment - Current and Future Tools. Breast Care (Basel) (2009) 0.76
The safety of chemotherapy for breast cancer patients with hepatitis C virus infection. J Cancer (2013) 0.76
Urban-Rural Variations in Quality-of-Life in Breast Cancer Survivors Prescribed Endocrine Therapy. Int J Environ Res Public Health (2017) 0.75
Clinicopathological features and treatment sensitivity of elderly Chinese breast cancer patients. Oncol Lett (2010) 0.75
Anti-cancer effects of Kochia scoparia fruit in human breast cancer cells. Pharmacogn Mag (2014) 0.75
Optimal management of breast cancer in the elderly patient: current perspectives. Clin Interv Aging (2015) 0.75
Prognostic impact of breast cancer subtypes in elderly patients. Breast Cancer Res Treat (2016) 0.75
Chemotherapy for 70-Year-Old Women with Breast Cancer in Germany: A Survey by the German Breast Group. Geburtshilfe Frauenheilkd (2013) 0.75
Association of Pre-Chemotherapy Peripheral Blood Pro-Inflammatory and Coagulation Factors with Physical Function in Women with Breast Cancer. Oncologist (2017) 0.75
A small cosmid for efficient cloning of large DNA fragments. Gene (1980) 22.61
Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol (2000) 16.83
Cosmids: a type of plasmid gene-cloning vector that is packageable in vitro in bacteriophage lambda heads. Proc Natl Acad Sci U S A (1978) 16.33
Strategies for subtypes--dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol (2011) 13.95
Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013. Ann Oncol (2013) 9.68
Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009. Ann Oncol (2009) 9.18
Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial. Lancet (2007) 8.08
Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007. Ann Oncol (2007) 7.33
First results from the International Breast Cancer Intervention Study (IBIS-I): a randomised prevention trial. Lancet (2002) 6.02
Analysis of survival by tumor response. J Clin Oncol (1983) 5.91
Meeting highlights: international expert consensus on the primary therapy of early breast cancer 2005. Ann Oncol (2005) 5.41
Meeting highlights: International Consensus Panel on the Treatment of Primary Breast Cancer. Seventh International Conference on Adjuvant Therapy of Primary Breast Cancer. J Clin Oncol (2001) 5.31
Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood. N Engl J Med (1991) 5.22
Accelerated titration designs for phase I clinical trials in oncology. J Natl Cancer Inst (1997) 4.60
School-based programs to reduce sexual risk behaviors: a review of effectiveness. Public Health Rep (1994) 4.50
Redressing the balance--the ethics of not entering an eligible patient on a randomised clinical trial. Ann Oncol (1992) 4.41
Low-dose oral methotrexate and cyclophosphamide in metastatic breast cancer: antitumor activity and correlation with vascular endothelial growth factor levels. Ann Oncol (2002) 4.32
Overview of the main outcomes in breast-cancer prevention trials. Lancet (2003) 4.31
Female sex and drug dose as risk factors for late cardiotoxic effects of doxorubicin therapy for childhood cancer. N Engl J Med (1995) 4.03
Periodontal infection as a possible risk factor for preterm low birth weight. J Periodontol (1996) 4.02
Improved outcome for children with acute lymphoblastic leukemia: results of Dana-Farber Consortium Protocol 91-01. Blood (2001) 3.93
Is chemotherapy alone adequate for young women with oestrogen-receptor-positive breast cancer? Lancet (2000) 3.79
Letrozole, a new oral aromatase inhibitor for advanced breast cancer: double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate. J Clin Oncol (1998) 3.69
Plasmids useable as gene-cloning vectors in an in vitro packaging by coliphage lambda: "cosmids". Gene (1978) 3.66
PTEN loss of expression predicts cetuximab efficacy in metastatic colorectal cancer patients. Br J Cancer (2007) 3.61
Characterization of mouse monoclonal antibodies specific for Friend murine leukemia virus-induced erythroleukemia cells: friend-specific and FMR-specific antigens. Virology (1981) 3.61
Cloning of the complete human cytomegalovirus genome in cosmids. Gene (1982) 3.55
Randomised comparison of procedures for obtaining informed consent in clinical trials of treatment for cancer. Br Med J (Clin Res Ed) (1986) 3.52
Meeting highlights: International Consensus Panel on the Treatment of Primary Breast Cancer. J Natl Cancer Inst (1998) 3.50
Role of immunohistochemical detection of lymph-node metastases in management of breast cancer. International Breast Cancer Study Group. Lancet (1999) 3.50
Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability study. J Clin Oncol (2000) 3.33
Quality-of-life-adjusted survival analysis of interferon alfa-2b adjuvant treatment of high-risk resected cutaneous melanoma: an Eastern Cooperative Oncology Group study. J Clin Oncol (1996) 3.30
Adjuvant chemotherapy for adult soft tissue sarcomas of the extremities and girdles: results of the Italian randomized cooperative trial. J Clin Oncol (2001) 3.29
Body mass index as a prognostic feature in operable breast cancer: the International Breast Cancer Study Group experience. Ann Oncol (2004) 3.29
Resting and activated endothelial cells are increased in the peripheral blood of cancer patients. Blood (2001) 3.24
Can different patient satisfaction survey methods yield consistent results? Comparison of three surveys. BMJ (1996) 3.20
Prognostic importance of c-erbB-2 expression in breast cancer. International (Ludwig) Breast Cancer Study Group. J Clin Oncol (1992) 3.17
Prognostic impact of amenorrhoea after adjuvant chemotherapy in premenopausal breast cancer patients with axillary node involvement: results of the International Breast Cancer Study Group (IBCSG) Trial VI. Eur J Cancer (1998) 3.03
Activation of a transposable element in the germ line but not the soma of Caenorhabditis elegans. Nature (1987) 3.00
Gonadotrophin stimulation test ovarian function. Br Med J (1968) 2.99
Adjuvant chemotherapy in oestrogen-receptor-poor breast cancer: patient-level meta-analysis of randomised trials. Lancet (2008) 2.91
Organization and function of an accident flying squad. Br Med J (1966) 2.88
Primary extranodal non-Hodgkin's lymphomas. Part 1: Gastrointestinal, cutaneous and genitourinary lymphomas. Ann Oncol (1997) 2.87
Primary diffuse large B-cell lymphoma of the breast: prognostic factors and outcomes of a study by the International Extranodal Lymphoma Study Group. Ann Oncol (2007) 2.85
The Gothenburg breast screening trial: first results on mortality, incidence, and mode of detection for women ages 39-49 years at randomization. Cancer (1997) 2.75
Instability of palindromic DNA in Escherichia coli. Cold Spring Harb Symp Quant Biol (1981) 2.75
Identifying breast cancer patients at risk for Central Nervous System (CNS) metastases in trials of the International Breast Cancer Study Group (IBCSG). Ann Oncol (2006) 2.72